Hysterectomy

Medical Simulation Global Market to Reach $4.1 Billion by 2027 at a CAGR of 13.68%

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Environment, Hospital, Artificial intelligence, Patient safety, Appendectomy, Physician, Virtual reality, Ramakanta Panda, Nursing, Hysterectomy, Cholecystectomy, Robotics, Surgeon, Feedback, Augmented reality, AR, Co-production (public services), Medical device, Growth

The global medical simulation market size reached US$ 1.9 Billion in 2021.

Key Points: 
  • The global medical simulation market size reached US$ 1.9 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 4.1 Billion by 2027, exhibiting a CAGR of 13.68% during 2021-2027.
  • Medical simulation uses body manikins, task trainers and virtual reality (VR)-based systems for laparoscopic, gynecological, cardiovascular, arthroscopic, spinal, endovascular, dental and eye simulation.
  • The publisher provides an analysis of the key trends in each sub-segment of the global medical simulation market report, along with forecasts at the global, regional and country level from 2022-2027.

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System

Retrieved on: 
Wednesday, November 30, 2022
Morcellator, Fibroid, Communication, American College of Obstetricians and Gynecologists, Malignancy, American College, Multimedia, Safety, AAGL, Patient, Hysterectomy, Disease, Committee, ACOG, Olympus, FDA, Pharmaceutical industry, Medical device, Birth control, Gynaecology

CENTER VALLEY, Pa., Nov. 30, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the market launch of the moresolution™ Power Morcellator, which is manufactured by TROKAMED GmbH  and is available in the U.S. through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.

Key Points: 
  • The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.
  • Current FDA Guidance on power morcellator labeling requires that all power morcellators marketed in the U.S. be used with a compatible, FDA-cleared containment device.1 The Olympus Contained Tissue Extraction System comprises the PneumoLiner, a first-of-its-kind containment device, and the moresolution Morcellator, which together provide select patients a laparoscopic surgical option as an alternative to open hysterectomy or open myomectomy for tissue removal.
  • Contained tissue extraction is not indicated for use withwomen who have a known or suspected malignancy.
  • Features and benefits of the moresolution Morcellator include:
    "We are excited to offer a new power morcellation solution for minimally invasive gynecological procedures," said Richard Reynolds, President of the Medical System Group at Olympus America, Inc. "Olympus supports the safe use of power morcellators with a contained extraction system according to FDA guidance.

Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Hysterectomy, Abnormal uterine bleeding, Woman, Uterus, AUB, Conference, Minerva, Medical device

SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY.

Key Points: 
  • SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
  • The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies.
  • The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

Minerva Surgical Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Marketing, COVID-19, Adjustment, Abnormal uterine bleeding, EBITDA, Uterus, AUB, PPP, Telephone, Hospital, Projection, Government, Genesys, Hysterectomy, Risk, Depreciation, Woman, Medical device, Video game, Pharmaceutical industry, Aquaculture, Bookkeeping

SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022.

Key Points: 
  • SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022.
  • Overall gross margin was 54.1% for the third quarter of 2022, decreasing from the gross margin of 57.0% in the same period of 2021 and 59.0% reported in the second quarter of 2022.
  • Adjusted EBITDA for the third quarter of 2022 was negative $5.8 million, compared to negative $2.6 million for the same period in 2021, and negative $4.5 million in the second quarter of 2022.
  • Minerva Surgical will host a conference call to discuss the third quarter 2022 financial results after market close on Monday, November 14, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Medical Simulation Global Market Report 2022: Increasing Awareness of the Benefits of Simulation-Based Medical Learning Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
General Health, Radiology, Oncology, Training, Other Education, Hospitals, Health Technology, Education, Surgery, Nursing, Practice Management, Health, COVID-19, Environment, Hospital, Artificial intelligence, Patient safety, Appendectomy, Physician, Virtual reality, Ramakanta Panda, Nursing, Hysterectomy, Cholecystectomy, Robotics, Surgeon, Feedback, Augmented reality, AR, Co-production (public services), Medical device, Growth

The "Medical Simulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Simulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global medical simulation market size reached US$ 1.9 Billion in 2021.
  • Moreover, the increasing awareness regarding the benefits of simulation-based learning among the masses is providing a thrust to the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global medical simulation market report, along with forecasts at the global, regional and country level from 2022-2027.

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
Monday, November 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

Momentis Announces First Adoption of Anovo™ Surgical System in Texas by Medical City Plano

Retrieved on: 
Monday, November 14, 2022
Salpingectomy, Technology, MD, Salpingoophorectomy, Ovarian cyst, Scar, Infection, FDA, Entrepreneurship, Shoulder, Elbow, Hysterectomy, Patient, CEO, Surgeon, Hospital, Dentistry

PLANO, Texas and FORT LAUDERDALE, Fla., Nov. 14, 2022 /PRNewswire/ -- Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Medical City Plano has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including benign hysterectomies. Medical City Plano is the first medical facility in Texas to adopt this system.

Key Points: 
  • PLANO, Texas and FORT LAUDERDALE, Fla., Nov. 14, 2022 /PRNewswire/ -- Momentis Surgical Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Medical City Plano has acquired the Anovo Surgical System for use in transvaginal benign gynecological procedures including benign hysterectomies.
  • Medical City Plano is the first medical facility in Texas to adopt this system.
  • "We are pleased to see significant progress in bringing the Anovo Surgical System, the first surgical robot of its kind, to more healthcare facilities and patients across the U.S. including acute care hospitals such as Medical City Plano," said Dvir Cohen, CEO and Co-Founder of Momentis.
  • Momentis Surgical Ltd is a medical device company founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary, Momentis Surgical Inc., based in Fort Lauderdale, Florida.

Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Monday, November 7, 2022
Nasdaq, GLOBE, Telephone, Hysterectomy, Woman, Minerva, Uterus, Abnormal uterine bleeding, AUB, Company, Holocene, Medical device

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.

Key Points: 
  • SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.
  • It will now report its third quarter 2022 financial results on Monday, November 14, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Groundbreaking Fibroid Workshop for Patients at the AAGL's Global Congress on Minimally Invasive Gynecologic Surgery

Retrieved on: 
Monday, November 7, 2022
Linda, Aurora, Research, Education, Fibroid, Fiction, Communications manager, Congress, Woman, AAGL, Safety, Uncertainty, DRS, Trust, MT, Physician, Surgeon, Marketing, Hysteroscopy, Hysterectomy, Association, Patient, American Association, Communication, Medicine

CYPRESS, Calif., Nov. 7, 2022 /PRNewswire-PRWeb/ -- The options for medical intervention and surgical procedures for fibroid disorders have become more complex and fragmented with many patients reporting difficulty and uncertainty in deciphering fibroid treatment options. This first-of-its-kind, patient-centric webinar, hosted by AAGL members, Drs. Linda Bradley, Jessica Opoku-Anane, Cara King, and Sony Sukhbir Singh, seeks to educate patients on state-of-the-art therapeutics and minimally invasive surgical options for myomectomy, hysterectomy, and hysteroscopy, in addition to non-surgical options for fibroids. Presenters will share recent medical and surgical updates, help patients identify questions to ask their provider, and encourage strategies for self-care and self-advocacy throughout their fibroid journey.

Key Points: 
  • Typically held solely for physicians, AAGL's Global Congress is the premier scientific conference for gynecologic surgeons from around the world.
  • CYPRESS, Calif., Nov. 7, 2022 /PRNewswire-PRWeb/ -- The options for medical intervention and surgical procedures for fibroid disorders have become more complex and fragmented with many patients reporting difficulty and uncertainty in deciphering fibroid treatment options.
  • AAGL's Global Congress, held in Aurora, Colorado, December 1-4, 2022, offers high-quality education and cutting-edge best practices in minimally invasive gynecologic surgery.
  • About AAGL: AAGL is an international professional medical association of laparoscopic surgeons and the global leader in minimally invasive gynecologic surgery.

ChristianaCare Creates Business Health Solutions to Offer Its Award-Winning Health Care Services to Employers Regionally and Nationally

Retrieved on: 
Wednesday, November 2, 2022
News, Heart, Population, Health, Hospital, Business development, Center, U.S. News & World Report, NPS, American College of Cardiology, GLOBE, Industry, COVID-19, Program, Computerworld, Cardiothoracic surgery, Business, Workforce, Healthgrades, Vaccination, American College, Forbes, Bariatric surgery, Clinical Excellence Awards, Patient, Hysterectomy, The Last Best Place, IDG, Bed, Society, Cardiology, Health insurance, Medicine, Pharmaceutical industry, Newsweek

ChristianaCare Business Health Solutions leverages the nationally recognized clinical expertise of ChristianaCare to provide high-quality, cost-effective health care services to businesses and employers, said Joe Miralles, vice president of Business Development at ChristianaCare.

Key Points: 
  • ChristianaCare Business Health Solutions leverages the nationally recognized clinical expertise of ChristianaCare to provide high-quality, cost-effective health care services to businesses and employers, said Joe Miralles, vice president of Business Development at ChristianaCare.
  • We offer direct-to-employer packages to keep health care costs down, improve employee wellness and workforce productivity and integrate services to offer accessible, high-quality, convenient care through enhanced coordination.
  • Headquartered in Wilmington, Delaware, ChristianaCare is one of the countrys most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs.
  • With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.